Literature DB >> 19471557

A case of inguinal lymph node squamous cell carcinoma of unknown origin, accompanied with carcinoma in situ of cervix.

Sung-Ha Lee1, Min-Jung Kim, Hee-Jung Lee, Sa-Jin Kim, Jong-Sup Park, Soo-Young Hur.   

Abstract

Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3-5% of all malignant neoplasms. CUP represents a heterogeneous group of metastatic tumors for which no primary site can be detected following a thorough medical history, careful clinical examination, and extensive diagnostic work-up. Several authors have reported poor prognosis of this malignancy, because there is no consensus on diagnostic guidelines and optimal therapy. Historically, chemotherapy has been the cornerstone of treatment for patients with CUP. We experienced a case of inguinal lymph node squamous cell carcinoma of unknown origin, accompanied with carcinoma in situ of the cervix. We report this case with a brief review of the literatures.

Entities:  

Keywords:  Inguinal lymph node; Metastatic cancer of unknown primary site

Year:  2008        PMID: 19471557      PMCID: PMC2676454          DOI: 10.3802/jgo.2008.19.2.145

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  16 in total

1.  Unknown primary site of serous papillary adenocarcinoma involving inguinal, iliac and obturator lymph nodes co-existing with endometrial adenocarcinoma.

Authors:  N Burbos; K Blanas; S D Epurescu; R Lonsdale; J J Nieto
Journal:  J Obstet Gynaecol       Date:  2007-07       Impact factor: 1.246

2.  Management of patients with cancer of unknown primary site.

Authors:  J D Hainsworth; F A Greco
Journal:  Oncology (Williston Park)       Date:  2000-04       Impact factor: 2.990

3.  Inguinal node metastases.

Authors:  H A Zaren; E M Copeland
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

Review 4.  Unknown primary tumours.

Authors:  H F Hillen
Journal:  Postgrad Med J       Date:  2000-11       Impact factor: 2.401

5.  Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.

Authors:  F A Greco; J B Erland; L H Morrissey; H A Burris; R C Hermann; R Steis; D Thompson; J Gray; J D Hainsworth
Journal:  Ann Oncol       Date:  2000-02       Impact factor: 32.976

6.  Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases.

Authors:  A Guarischi; T J Keane; T Elhakim
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

Review 7.  Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.

Authors:  F A Greco; J D Hainsworth
Journal:  Semin Oncol       Date:  1994-10       Impact factor: 4.929

8.  Evaluation of six tumor markers in patients with carcinoma of unknown primary.

Authors:  N Pavlidis; J Kalef-Ezra; E Briassoulis; D Skarlos; P Kosmidis; K Saferiadis; E Bairaktari; D Bafaloukos; A Maravegias; D Theoharis
Journal:  Med Pediatr Oncol       Date:  1994

9.  Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study.

Authors:  N Pavlidis; P Kosmidis; D Skarlos; E Briassoulis; M Beer; D Theoharis; D Bafaloukos; A Maraveyas; G Fountzilas
Journal:  Ann Oncol       Date:  1992-09       Impact factor: 32.976

Review 10.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.